Literature DB >> 20032173

Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication.

Ian D Simon1, Nico van Rooijen, John K Rose.   

Abstract

Our previous studies using intranasal inoculation of mice with vesicular stomatitis virus (VSV) vaccine vectors showed persistence of vector genomic RNA (gRNA) for at least 60 days in lymph nodes in the absence of detectable infectious virus. Here we show high-level concentration of virus and gRNA in lymph nodes after intramuscular inoculation of mice with attenuated or single-cycle VSV vectors as well as long-term persistence of gRNA in the lymph nodes. To determine if the persistence of gRNA was due to ongoing viral replication, we developed a tagged-primer approach that was critical for detection of VSV mRNA specifically. Our results show that VSV gRNA persists long-term in the lymph nodes while VSV mRNA is present only transiently. Because VSV transcription is required for replication, our results indicate that persistence of gRNA does not result from continuing viral replication. We also performed macrophage depletion studies that are consistent with initial trapping of VSV gRNA largely in lymph node macrophages and subsequent persistence elsewhere in the lymph node.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032173      PMCID: PMC2838132          DOI: 10.1128/JVI.02052-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  Marginal zone macrophages and immune responses against viruses.

Authors:  Stephan Oehen; Bernhard Odermatt; Urs Karrer; Hans Hengartner; Rolf Zinkernagel; Constantino López-Macías
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

3.  RNA synthesis of vesicular stomatitis virus. V. Interactions between transcription and replication.

Authors:  S M Perlman; A S Huang
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

4.  Measles-virus antibody and antigen in subacute sclerosing panencephalitis.

Authors:  J H Connolly; I V Allen; L J Hurwitz; J H Millar
Journal:  Lancet       Date:  1967-03-11       Impact factor: 79.321

5.  Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA.

Authors:  J K Craggs; J K Ball; B J Thomson; W L Irving; A M Grabowska
Journal:  J Virol Methods       Date:  2001-05       Impact factor: 2.014

6.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.

Authors:  J Erik Johnson; John W Coleman; Narender K Kalyan; Priscilla Calderon; Kevin J Wright; Jennifer Obregon; Eleanor Ogin-Wilson; Robert J Natuk; David K Clarke; Stephen A Udem; David Cooper; R Michael Hendry
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

9.  Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.

Authors:  Sagar U Kapadia; Ian D Simon; John K Rose
Journal:  Virology       Date:  2008-04-08       Impact factor: 3.616

View more
  14 in total

Review 1.  From optical bench to cageside: intravital microscopy on the long road to rational vaccine design.

Authors:  Heather D Hickman; Jack R Bennink; Jonathan W Yewdell
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 2.  Viruses - from pathogens to vaccine carriers.

Authors:  Juliana C Small; Hildegund C J Ertl
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

3.  Measles immunometrics.

Authors:  Theodore C Pierson; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-30       Impact factor: 11.205

4.  A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.

Authors:  Alex B Ryder; Linda Buonocore; Leatrice Vogel; Raffael Nachbagauer; Florian Krammer; John K Rose
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

5.  The Propagation, Quantification, and Storage of Vesicular Stomatitis Virus.

Authors:  Alaa A Abdelmageed; Maureen C Ferran
Journal:  Curr Protoc Microbiol       Date:  2020-09

Review 6.  Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells.

Authors:  L S Cauley; L Lefrançois
Journal:  Mucosal Immunol       Date:  2012-11-07       Impact factor: 7.313

7.  Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak.

Authors:  Matthew L Boisen; Eghosa Uyigue; John Aiyepada; Katherine J Siddle; Lisa Oestereich; Diana K S Nelson; Duane J Bush; Megan M Rowland; Megan L Heinrich; Philomena Eromon; Adeyemi T Kayode; Ikponmwosa Odia; Donatus I Adomeh; Ekene B Muoebonam; Patience Akhilomen; Grace Okonofua; Blessing Osiemi; Omigie Omoregie; Michael Airende; Jacqueline Agbukor; Solomon Ehikhametalor; Chris Okafi Aire; Sophie Duraffour; Meike Pahlmann; Wiebke Böhm; Kayla G Barnes; Samar Mehta; Mambu Momoh; John Demby Sandi; Augustine Goba; Onikepe A Folarin; Ephraim Ogbaini-Emovan; Danny A Asogun; Ekaete A Tobin; George O Akpede; Sylvanus A Okogbenin; Peter O Okokhere; Donald S Grant; John S Schieffelin; Pardis C Sabeti; Stephan Günther; Christian T Happi; Luis M Branco; Robert F Garry
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

8.  Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression.

Authors:  Emily A Gomme; Christoph Wirblich; Sankar Addya; Glenn F Rall; Matthias J Schnell
Journal:  PLoS Pathog       Date:  2012-10-11       Impact factor: 6.823

9.  Agonistic anti-CD40 enhances the CD8+ T cell response during vesicular stomatitis virus infection.

Authors:  Julianne M Zickovich; Susan I Meyer; Hideo Yagita; Joshua J Obar
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

10.  Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.

Authors:  Kenta Tezuka; Kazu Okuma; Madoka Kuramitsu; Sahoko Matsuoka; Reiko Tanaka; Yuetsu Tanaka; Isao Hamaguchi
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.